Open AccessBUDESONIDE, A LOCALLY ACTING STEROID, PREVENTS GRAFT REJECTION IN A RAT MODEL OF INTESTINAL TRANSPLANTATION1
Author(s) -
Necdet Özçay,
Jonathan P. Fryer,
David Grant,
David W. Freeman,
Bertha García,
Robert Zhong
Publication year - 1997
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/00007890-199705150-00006
Subject(s) - immunosuppression , medicine , prednisolone , budesonide , adverse effect , endocrinology , transplantation , methylprednisolone , corticosteroid , gastroenterology
The requirement for potent systemic immunosuppression to prevent intestinal graft rejection has resulted in high rates of infection and post-transplant lymphoproliferative disease. Budesonide (BUD) is a locally acting steroid that is almost completely metabolized during its first pass through the intestinal wall and liver. The present study examined whether BUD could prevent small bowel allograft rejection without causing the adverse systemic effects associated with prednisolone.